Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis

Robert L. Keith, Mark W. Geraci, S. Patrick Nana-Sinkam, Richard M. Breyer, Tyler M. Hudish, Amy M. Meyer, Alvin M. Malkinson, Lori D. Dwyer-Nield

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Background: Manipulating prostaglandin (PG) production modulates tumor development. Elevated PGI2 production prevents murine lung cancer, while decreasing PGE2 content protects against colon cancer. PGE 2 receptor subtype 2 (EP2)-deficient mice were hypothesized to be resistant to lung tumorigenesis. Materials and Methods: EP2 null BALB/c mice and their wild-type littermates were exposed to an initiationpromotion carcinogenesis protocol and lung tumorigenesis was examined. Chronic lung inflammation was induced to determine whether EP 2 ablation influenced inflammatory cell infiltration. Results: Tumor multiplicity in EP2 null mice was 34% lower than in their wild-type littermates (21.9±3.0 vs. 14.5±2.9 tumors/mouse, p<0.001). The lung tumor burden, an indicator of growth rate, also declined (57%, p<0.05). All the mice exhibited similar inflammatory cell infiltration. Conclusion: PGE 2, acting through EP2, enhanced lung tumorigenesis through a mechanism that may be distinct from its proinflammatory activity. Thus, EP2 is a potential target for novel chemoprevention strategies.

Original languageEnglish (US)
Pages (from-to)2857-2861
Number of pages5
JournalAnticancer Research
Volume26
Issue number4 B
StatePublished - Jul 1 2006

    Fingerprint

Keywords

  • Chronic pulmonary inflammation
  • Downstream prostaglandin receptors
  • EP
  • Two-stage carcinogenesis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Keith, R. L., Geraci, M. W., Nana-Sinkam, S. P., Breyer, R. M., Hudish, T. M., Meyer, A. M., Malkinson, A. M., & Dwyer-Nield, L. D. (2006). Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Research, 26(4 B), 2857-2861.